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Vulvar cancer accounts for 0.5% of all malignancies; the most
frequent histologic type is squamous cell carcinoma, which affects
predominantly elderly women. From 1940 radical vulvectomy
with bilateral inguinofemoral lymphadenectomy has been the stan-
dard treatment for these patients. This operation entails complete
removal of the vulva, mons pubis, inguinofemoral nodes and
sometimes pelvic nodes. Lymphadenectomy may result in high
morbidity, with wound breakdown, wound infection occurring in
up to 85% of the cases and chronic lymphoedema reported in
15–20% of the patients (Podratz et al, 1982).
In the last 10 years the surgical procedure has become more
conservative (Sutton et al, 1991; Cavanagh, 1997) and in patients
with early cancer a modified radical vulvectomy or a wide exci-
sion of the tumour was shown to be adequate to eradicate the local
vulvar lesion. However, although groin dissection is considered
necessary in patients with clinically positive nodes, the procedure
may be an overtreatment when inguinal nodes are free of disease.
A reduction of the surgical aggressiveness in the groin has been
attempted, resulting sometimes in an increase of recurrence rate
(Stehman et al, 1992; Burke et al, 1995). In 1977, Cabanas intro-
duced the sentinel node (SN) concept for penile carcinoma,
suggesting to select subjects for complete lymphadenectomy
(Cabanas, 1977). In 1979, Di Saia et al, considering the first level
of inguinofemoral lymph nodes, superficial nodes, as the first
draining site in vulvar cancer, proposed a limited dissection of
these nodes if they resulted free of disease (Di Saia et al, 1979).
However, a Gynaecology Oncology Group (GOG) controlled 
clinical trial demonstrated a decrease of disease-free survival and
increase in recurrence rate when this technique was applied in a
large multicentric study (Stehman et al, 1992).
In 1992, Morton et al applied the concept of SN in cutaneous
melanoma (Morton et al, 1992a, 1992b), employing the blue dye
technique in order to identify SN for biopsy. Levenback et al
(1994, 1995) applied this technique in vulvar squamous cell
cancer, finding that SN status was predictive of the whole groin
node pathologic status. However, with blue dye the SN was missed
in 34% of the evaluated groins and no lymphatic channel was
identified in 24% of the patients.
Lymphoscintigraphy is another method for localizing SN; it is a
non-invasive and well-established technique for evaluating the
anatomical pattern of lymphatic distribution and it has been
proven to be a suitable method to study the lymphatic drainage
pathways of the vulva (Iversen and Aas, 1983, Barton et al, 1992).
Associated with gamma-probe guided surgery, lymphoscintig-
raphy has recently been proposed as a more suitable technique
than blue dye injection to remove during surgery the sentinel
nodes in melanoma and breast cancer patients (Alex et al, 1993;
Krag et al, 1993). In these patients the reliability and accuracy of
the procedure has been demonstrated by several studies (Van der
Veen et al, 1994; Veronesi et al, 1997), while some preliminary
reports on ten patients showed that lymphoscintigraphic method is
feasible for the identification of the SN in squamous cell cancer of
the vulva as well (De Cesare et al, 1997; De Hullu et al, 1998).
The present study is proposed in order to verify the predictive
value of the SN status in a larger series of patients.
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Summary Lymph node pathologic status is the most important prognostic factor in vulvar cancer; however, complete inguinofemoral node
dissection is associated with significant morbidity. Lymphoscintigraphy associated with gamma-probe guided surgery reliably detects sentinel
nodes in melanoma and breast cancer patients. This study evaluates the feasibility of the surgical identification of sentinel groin nodes using
lymphoscintigraphy and a gamma-detecting probe in patients with early vulvar cancer. Technetium-99m-labelled colloid human albumin was
administered perilesionally in 37 patients with invasive epidermoid vulvar cancer (T1–T2) and lymphoscintigraphy performed the day before
surgery. An intraoperative gamma-detecting probe was used to identify sentinel nodes during surgery. A complete inguinofemoral node
dissection was then performed. Sentinel nodes were submitted separately to pathologic evaluation. A total of 55 groins were dissected in 37
patients. Localization of the SN was successful in all cases. Eight cases had positive nodes: in all the sentinel node was positive; the sentinel
node was the only positive node in five cases. Twenty-nine patients showed negative sentinel nodes: all of them were negative for lymph node
metastases. Lymphoscintigraphy and sentinel-node biopsy under gamma-detecting probe guidance proved to be an easy and reliable
method for the detection of sentinel node in early vulvar cancer. This technique may represent a true advance in the direction of less
aggressive treatments in patients with vulvar cancer. © 2000 Cancer Research Campaign
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Patients and administration technique
From May 1996 to September 1998, 37 consecutive patients with
early invasive squamous-cell vulvar cancer were studied. Patients
with clinically positive groin nodes, pregnant or lactating patients
were excluded from the study. Thirty-three patients presented a
primary tumour; four patients had a previous diagnostic surgical
excision of the lesion. Seventeen patients had T1 and 20 had T2
vulvar lesions, without clinical evidence of regional lymph-node
metastases. Nineteen patients had unilateral lesions and 18
patients had midline lesions (Table 1). A midline lesion is defined
as a tumour located within 2 cm of the midline. An informed
consent for the participation in the study was obtained from all the
patients.
Lymphoscintigraphy was performed the day before surgery to
establish lymphatic drainage and to define the location of the
sentinel nodes. Colloid particles of human albumin ranging from
50 to 80 nm in size (Nanocoll, supplied by Amersham-Sorin,
Saluggia, Italy) were used. The colloids were labelled with 99mTc
freshly eluted from a generator and submitted to a quality control
for free technetium according with manufacturer recommenda-
tions. Radiochemical purity of the tracers was always over 95%.
Generally 5 MBq of 99mTc-colloids per injection in a volume of 0.1
ml were administered subcutaneously at the junction of the tumour
and the normal skin, through a 25-gauge needle, followed by 0.1
ml of air in order to ensure the complete tracer administration. The
number of injections ranged from two to four, depending on the
site and shape of the lesions. The total dose administered to each
patient was 10–20 MBq. When the lesion was clearly unilateral
the administration of the tracer was performed in two sites close to
the tumour (at 6 and 12 o’clock positions); in cases of lesions near
to midline four injections around the tumour at 3, 6, 9, 12 o’clock
positions were done.
Scintigraphic studies
Planar scans of the vulvar and inguinal areas in anterior and lateral
projections were obtained after 5–20 min (early) and 3 h (late)
from radiotracer injection (Figures 1 and 2). Each acquisition
lasted 5 min. Delayed images were acquired when no drainage
was documented. After acquisition of the last scan, a cutaneous
marker with a suitable pen was positioned in correspondence to
the first lymph node chronologically revealed by the gamma-
camera.
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Table 1 Summary of sentinel node findings in 37 vulvar lesions
Primary lesion site No. pts SN detection Groin(s) involved No. of lymph nodes studied
(LS plus GPD)
Ipsilat. Bilat. SN non-SN
Lateral 19 19 – 30 (6*) 219 (6*)
100%
Midline 18 5 13 49 (4*) 408 (1*)
Total
37 50 79 (10*) 627 (7*)
(*) = No. of positive lymph nodes.
A
B
Figure 1 Lymphoscintigraphy in patient with a midline vulvar lesion reveals
an intensively radioactive sentinel node (arrow) in the left groin in the early
image (A). A second less intense radioactive focus is cleared 3 h post
injection (B). No sentinel nodes are revealed in the right side. The injection
site is on the lower of the figure
}Surgical procedure
A standard surgical approach, consisting of wide radical excision
of the tumour, hemivulvectomy or radical vulvectomy, was used in
all patients. For unilateral lesions equal to or less than 2 cm in
diameter ipsilateral groin dissection was performed. When the
lesion was greater than 2 cm or in the midline, bilateral groin
dissection was done.
Before groin dissection was carried out, the gamma-detecting
probe (GDP) MR 100, from Po.li.tech. (L’Aquila, Italy), was
inserted in a sterile glove and used by the surgeon to localize the
area emitting the higher signal of gamma-ray emission; then a 
3 cm incision was made and SN excised and labelled as ‘sentinel’
lymph node. When more than one SN was detected, the nodes
were ordered on the basis of radioactivity levels and sent sepa-
rately to the pathologist. A complete groin dissection was then
performed, according to Micheletti technique (Micheletti et al,
1990): superficial lymph nodes contained in the fat pad along the
inguinal ligament and deep femoral nodes lying below and above
the junction of the saphenous and femoral veins, with preservation
of the cribriform fascia, were removed. Then the GDP was slowly
passed over the removed surgical specimen, in order to exclude the
presence of other gamma-emitting foci in it.
Pathologic examination
A pathologist examined all the surgically-removed groin speci-
mens using standard technique. Briefly, the lymph nodes were
isolated fresh from groin fat tissue. Nodes >0.5 cm in diameter
were divided in two parts along the longitudinal axis, whereas
nodes <0.5 cm in the major axis were embedded in toto. Three
histological sections were obtained from each inclusion, at
different cut levels (at a distance between 0.3 and 1 mm), and were
stained with haematoxylin and eosin.
RESULTS
In all cases lymphoscintigraphy detected at least one lymph node
within 3 h after tracer administration. The mean number of nodes
localized was 1.7 in unilateral lesions; in 18 patients with midline
lesion an average of 3.3 SNs were detected (1.7 per groin). In 13
out of the 18 patients with midline lesions the SN was identified in
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A
B
Figure 2 Early (A) and delayed (B) scintigraphic images of the pelvis in
anterior view in patient with a tumoural lesion of the midline. In A only a
sentinel node in the right side is revealed; sentinel node of the controlateral
groin and some (several) bilateral faint foci of uptake are evident in B
Table 2 Pathologic results in the group of 8 patients with groin involvement
Eight out 37 patients with histologically positive SN
1 2 34567 8
Site of the tumour (R, M, L) R L L R M M M M
Size of the tumour (Ø mm) 20 30 8 35 60 20 3 12
Depth invasion (mm) 15 4 7 10 13 23 3 9
FIGO stage III III III III III III III III
No. of SN(s) 1 – – 2 1 1 0 1
Right groin (1*) (2*) (0*) (1*) (0*)
– 1 2–231 2
Left groin (1*) (2*) (1*) (0*) (1*) (1*)
No. of non-SNs 9 – – 8 6 8 9 9
Right groin (0*) (1*) (0*) (0*) (0*) (0*)
– 13 13 – 10 20 7 8
Left groin (0*) (5*) (1*) (0*) (0*) (0*)
R = right; M = midline; L = left. (*) = No. of positive lymph nodes.both groins. In five patients no contralateral lymphatic drainage
was documented. In most cases (33/37, 89%) the SN was visual-
ized in less than 30 min and in four cases in the late images; in two
of these patients delayed images were required (later than 10 h
post-injection). The mean number of SN surgically detected with
the GDP per groin was 1.4 (range 0–4). The total number of nodes
removed was 736 (mean 13; range 9–23) (Table 1).
Eight out of 37 cases had positive nodes (Table 2); the SN was
the only positive node in six cases; in the remainder three, in one
case two SNs and one non-SN were positive; in one patient the SN
was one of two positive nodes, while in the last case two SNs and
other five non-SN were found to have metastases. Twenty-nine
patients showed negative SN: all of them were histologically nega-
tives. In the five out of 18 patients with midline lesion, with only
one groin showed lymphatic drainage, controlateral lymphadenec-
tomy did not show metastatic nodes.
Dosimetry
The absorbed dose to the inoculated area and lymph nodes were
estimated at 0.85 ± 0.5 mGy MBq–1 and 0.05 ± 0.03 mGy MBq–1
respectively. Because of the small quantity of material injected and
the fact that it was mainly concentrated in tissue that was removed,
the adsorbed dose to the site of injection and other tissue was
negligible. The air kerma rate at 0, at 50 and at 100 cm from the
injection site immediately before surgery (about 20 h after injec-
tion) was 4.5 ± 1.0, 1.5 ± 0.4 and 0.9 ± 0.3 mGy h–1 respectively.
The absorbed dose to the surgeons’ hands after 100 cases using 
20 MBq per case would be 9.0 ± 1.6 mSv, corresponding to less
than 2% and 0.2% of the recommended limits for the population
and the exposed personnel respectively (ICPR, 1991).
The procedure is therefore safe and does not pose any radiation
risk for patients, hospital staff, relatives or surgical team.
DISCUSSION
Sentinel-node biopsy by means of GDP after lymphoscintigraphy
proved to be an accurate technique in melanoma and breast cancer
patients, in order to predict lymph node status. Several studies
performed using both blue dye and lymphoscintigraphic methods
demonstrated so far that the sentinel node concept is functionally
valid and may avoid in the near future many lymphadenectomies
in early cancer (Albertini et al, 1996; Veronesi et al, 1997;
Bartolomei et al, 1998; Krag et al, 1998). Sentinel node concept
seems to be applicable to vulvar cancer as well: Levenback in two
consecutive series of 9 and 21 patients studied with blue dye tech-
nique found that in no case was there a regional node positive
when the sentinel node was negative. However, the blue dye
method is affected by a low sensitivity in identifying the sentinel
node. Recently, two different preliminary studies in vulvar cancer
(De Cesare et al, 1997; De Hullu et al, 1998), both with ten
patients examined, had optimal results applying lymphoscintig-
raphy intraoperatively and the day before surgery respectively. In
both of them sensitivity and predictive value of the procedure were
100%. In the same way in our series of 37 patients with early
squamous cancer the status of the sentinel node was predictive of
the groin status in all cases and in five out of eight cases in which
inguinal nodes were involved, the sentinel node was the only
metastatic node. Furthermore, in two out of three cases in which
more than one node was found to be metastatic both of two SNs
were positive for metastases.
In 18 patients with midline lesions we never found positive
nodes in the groin in which no sentinel nodes were identified (five
patients). This finding indicates that in these conditions it is safe to
avoid every surgical procedure in the groin in which no lymphatic
drainage is documented at scan. In regard to the method, we
recommend performing lymphoscintigraphy the day before
surgery, in order to avoid an uncertain outcome about sentinel
node localization and the presence of drainage in each side of the
inguinal region as well. Nevertheless in 90% of the patients
sentinel nodes are visualized in less than 15 min and in fact tracer
administration could be done immediately before surgery. Indeed,
De Cesare et al (1997) used intraoperative administration of the
radiotracer with high sensitivity. However, in our experience
lymphatic drainage could occur later after administration,
rendering the procedure useless, particularly in patients who were
previously treated with partial surgical excision of the primary
lesion or with laser therapy. However, in our series including four
patients in this condition, surgical and laser treatments have not
affected the procedure and no misleading results were found in
patients previously treated.
We identified some potential limitations to the method:
• Although in our series no patients refused the injection of the
tracer, painful lesions could make the injection procedure less
tolerable; anaesthetic cream application 1 h before administra-
tion can resolve this problem.
• The high vascularity of the region and lesions can often
produce bleeding and blood vessel injection; this produces a
high background rate, which can disturb identification of the
nodes by the probe during surgery. It is important to avoid
intratumoural administration, injecting the tracer superficially
around the tumour and performing aspiration after puncture.
In summary, lymphoscintigraphy seems to be a feasible and
well-tolerated procedure for sentinel node localization, although
skilled operators are required. The technique is simple and is
ideally suited to be used in large multicentre studies to test the
predictivity of sentinel-node biopsy in early vulvar cancer.
Combining previous published data (Levenback et al, 1995; De
Cesare et al, 1997; De Hullu et al, 1998) with the present ones, SN
status was predictive of groin node positivity in a total of 78
patients. This result encourages the performance of a study on
selective lymphadenectomy in these patients. If we are successful
in staging groin lymph nodes by a simple biopsy, we could elimi-
nate the risk of complications associated with a complete
inguinofemoral node dissection for most patients and achieve
considerable savings in costs and morbidity.
In conclusion, sentinel-node biopsy under GDP guidance proved
to be an accurate method for intraoperative detection of sentinel
nodes. This technique may represent a true advance in the direction
of less aggressive treatments in patients with vulvar cancer.
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